Open Label Dose Escalation Trial of AB-205 (E-CEL^® cells) in Adults with Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT)

Abstract:

HDT-AHCT is a standard curative therapy for patients with relapsed, high risk lymphomas. Severe regimen-related toxicities (SRRT) occur frequently after AHCT, leading to high symptom burden and potentially limiting wider use. The cause of SRRT is thought to be diffuse injury to the organ vascular endothelial niches caused by off-target cytotoxic effects of HDT. Organs with high cell turnover such as oral-gastrointestinal (GI) tract are most affected. The cytotoxic effect impairs the renewal of mucosa, leading to mucositis, nausea, vomiting, and diarrhea. With loss of mucosal integrity, translocation of gut flora into the systemic circulation may lead to life-threatening infections.

AB-205 is an experimental engineered-cell therapy designed to repair damaged tissues and reduce SRRT. AB-205 contains E-CEL^® cells: allogeneic E4+ human umbilical vein endothelial cells.

47^th European Society for Blood and Marrow Transplantation Annual Meeting – Monday, March 15, 2021

C. Mulroney¹, M. Scordo², M. Abedi³, L.E. Budde⁴, B. Fakhri⁵, A. Pawarode⁶, B. Dholaria⁷, G. Shouse⁴, E. Kavalerchik⁸, S. Aggarwal⁸, M. Qazilbash⁹, P. Finnegan⁸, S. Giralt²

¹UCSD Moores Cancer Center, San Diego, United States, ²Memorial Sloan Kettering Cancer Center, New York, United States, ³UC Davis Medical Center, Sacramento, United States, ⁴City of Hope National Medical Center, Duarte, United States, ⁵University of California San Francisco, San Francisco, United States, ⁶University of Michigan, Ann Arbor, United States, ⁷Vanderbilt University, Nashville, United States, ⁸Angiocrine Bioscience, San Diego, United States, ⁹The University of Texas MD. Anderson Cancer Center, Houston, United States

Go to EBMT Meeting – 2021